French photonics market intelligence SME providing technology assessment and commercialization strategy across infrared sensing, LiDAR, and biophotonics.
TEMATYS is a French SME specializing in photonics market intelligence and technology consulting, based in the Saclay/Palaiseau photonics cluster near Paris. They provide market analysis, technology assessment, and business development support across the photonics value chain — from mid-infrared sensors and LiDAR to spectral imaging and biosensing. In EU consortia, they typically contribute market studies, exploitation strategies, and commercialization roadmaps, helping research teams understand where their photonic technologies fit in real markets. Their consistent involvement across diverse photonics projects signals deep sectoral knowledge rather than narrow technical specialization.
All seven H2020 projects involve photonics technologies, from mid-IR devices (MIRPHAB, MIR-BOSE) to LiDAR (OPHELLIA) and biosensing (BIOCELLPHE), indicating a cross-cutting market intelligence role.
MIRPHAB, MIR-BOSE, MULTIPLE, and NanoXim all involve spectral sensing and infrared photonics for chemical, industrial, and microscopy applications.
OPHELLIA (their largest-funded project at EUR 311K) focuses on erbium-doped on-chip lasers for LiDAR — TOF and FMCW approaches.
MULTIPLE combines hyperspectral imagers, OLED spectrometers, and deep learning for industrial process monitoring — bridging photonics with AI.
BIOCELLPHE applies photonic sensing to single-cell protein phenotyping, extending their photonics expertise into life sciences.
C3PO addressed laser uplink/downlink communication with space objects, an early project linking photonics to the space sector.
TEMATYS began its H2020 participation (2015–2017) focused on foundational photonics — space laser communications (C3PO) and mid-infrared device fabrication for chemical sensing (MIRPHAB, MIR-BOSE). From 2019 onward, their projects shifted decisively toward applied, market-ready photonic systems: multimodal spectral sensors combined with deep learning and edge computing (MULTIPLE), integrated on-chip LiDAR (OPHELLIA), and ultrasensitive biosensing platforms (BIOCELLPHE). The trajectory shows a clear move from component-level photonics toward system-level integration, AI-enhanced sensing, and application-specific markets like autonomous vehicles and healthcare diagnostics.
TEMATYS is moving toward photonics applications that intersect with AI and edge computing — expect future involvement in smart sensing, autonomous systems, and digital health.
TEMATYS has never coordinated a project, always joining as a participant — consistent with a consulting and market intelligence role where the technical lead sits elsewhere. With 66 unique partners across 14 countries in just 7 projects, they have a broad and non-repetitive network, suggesting they are sought after by different consortia rather than being locked into a fixed group. Their modest per-project funding (averaging EUR 169K) reflects a focused, specialized contribution rather than heavy R&D workload.
TEMATYS has built a wide European network of 66 unique partners across 14 countries through just 7 projects, averaging nearly 10 new partners per project. This breadth suggests they are a recognized name in European photonics consortia, valued for market-side expertise that complements technical partners.
TEMATYS occupies a rare niche: a photonics-specialist SME that bridges the gap between laboratory research and market reality. While most consortium partners bring hardware, algorithms, or testbeds, TEMATYS brings market intelligence — understanding which photonic technologies will find buyers, at what price, and in which sectors. For consortium builders, adding TEMATYS strengthens the exploitation and commercialization case, which reviewers increasingly demand in Horizon proposals.
